tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of James Quigley, 19 are a HOLD (54.29%), 13 are a BUY (37.14%), 3 are a SELL (8.57%).
Analyst James Quigley, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 42% that have a potential upside of 38.5% achieved within 171 days.
James Quigley’s has documented 62 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NVO, Novo Nordisk A/S at 13-Jan-2025.
Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/13/2023. The price target of $24 was fulfilled within 30 days with a profit of $9.02 (60.21%) receiving and performance score of 20.07.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$17
$-1.96 (-10.34%)
$17
1 years 8 months 4 days ago
(05-Feb-2024)
3/3 (100%)
$-0.27 (-1.56%)
96
Buy
1 years 8 months 23 days ago
(16-Jan-2024)
3/9 (33.33%)
$-3.83 (-50.86%)
633
Buy
$8.5
$-10.46 (-55.17%)
$10
1 years 10 months 4 days ago
(05-Dec-2023)
3/7 (42.86%)
$0.92 (12.14%)
253
Buy
$8.5
$-10.46 (-55.17%)
$10
1 years 10 months 4 days ago
(05-Dec-2023)
2/2 (100%)
$0.92 (12.14%)
106
Hold
$4.75
$-13.1 (-73.39%)
1 years 10 months 17 days ago
(22-Nov-2023)
1/2 (50%)
$0.2 (4.40%)
5
What Year was the first public recommendation made by James Quigley?
